Sequencing of the tumor combined with preclinical modeling studies suggested that an uncommon MAPK1 mutation found in 1–2% of HNSCC patients (E322K) mediated this clinical response [21]. This evidence concerns the gene MAPK1 and head and neck squamous cell carcinoma.